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2 
ABSTRACT 1 
Purpose: To examine quality of life and associated factors in people with Age-Related Macular 2 
Degeneration (AMD). 3 
Methods: 145 AMD participants (mean age 78.0 ±7.7 years) and 104 age- and gender- matched 4 
controls (mean age 78.1 ± 5.8 years) comprised the study populations for this case-control study. 5 
Depressive symptoms were measured with the Goldberg Anxiety and Depression (GAD) scale; 6 
general health and daily functioning was assessed with the Medical Outcomes Study Short Form 36 7 
and questions relating to assistance required for daily living activities.  8 
Results: People with AMD performed more poorly than controls on the GAD depression scale, and 9 
physical functioning subscale of SF-36. 44.4% of people with AMD had clinically significant 10 
depressive symptoms compared to 17.5% of controls (p<0.001). Multiple regression analysis 11 
revealed that AMD was independently associated with depressive symptoms and a path model 12 
indicated that AMD led to depressive symptoms both directly and indirectly via reduced general 13 
health and social functioning. 14 
Conclusion: Psychological and functional outcome measures are reduced in people with AMD. 15 
Earlier recognition and treatment of depressive symptoms in people with AMD may be crucial to 16 
maintaining quality of life in this group. 17 
 18 
 19 
20 
3 
INTRODUCTION 1 
Age Related Macular Degeneration (AMD) is the most common cause of visual loss in the elderly 2 
and one of the most daunting conditions for older people. In developed countries, it affects 10% of 3 
those in the age group 65-74 years and 30% of those 75 years and above
1
. AMD has been reported as 4 
the leading cause of blindness in people aged over 40 years 
2, 3
. 5 
Previous studies have examined the quality of life implications of AMD. Some have shown 6 
that the presence of AMD is associated with difficulties in performing daily tasks and emotional 7 
distress
4,5,7- 9
. Depression, in particular, has many adverse consequences if left untreated including 8 
decreased functioning and increased rates of institutionalisation and mortality
11, 12
. However, one 9 
study suggests that people with AMD report good life satisfaction despite difficulties with mobility 10 
and daily living activities as the condition challenged them to find new coping strategies
6
. These 11 
conflicting findings indicate that further study is required to determine the extent to which AMD can 12 
adversely affect emotional health and quality of life. 13 
In this study we assessed the presence of depressive symptoms and its relationship to 14 
comorbidities, physical activity levels, physical and social functioning and requirements for 15 
assistance with daily living related activities in large samples of people with AMD and age- and 16 
gender-matched controls. This information is important for understanding the full impact of AMD on 17 
psychosocial measures with implications for service provision. 18 
 19 
 20 
METHODS 21 
249 participants were recruited from a retinal clinic, the Macular Degeneration Foundation, 22 
Neuroscience Research Australia (previously the Prince of Wales Medical Research Institute) and 23 
the School of Optometry and Vision Science Clinic located within Sydney, Australia. The 24 
participants were divided into two groups: participants diagnosed with AMD, and participants 25 
4 
without reported ocular diseases (controls). At the Sydney Retina and Sydney Eye Clinics, staff 1 
provided potential subjects study information sheets with instructions to contact the primary 2 
researcher if they were interested in taking part in the study. Recruitment at the MD Foundation 3 
involved identifying potential subjects from the database and sending them information sheets and 4 
contact details of the researcher by mail. The data for the control subjects were collected by random 5 
selection matching for age and gender from the database for normal subjects of the Falls and Balance 6 
Research Group at Neuroscience Research Australia, which comprised 500 people aged 65 years and 7 
older. Inclusion criteria for the AMD group were people aged over 55 years, and with clinical 8 
evidence of AMD of at least AREDS Category 313 and visual acuity better than or equal to 6/60 and 9 
no ocular co-morbidities. The control group were those without self-reported ocular diseases 10 
(including cataract, macular degeneration, diabetic retinopathy, glaucoma etc) and age- and gender-11 
matched to the AMD group. This study was conducted with approval from the Human Research 12 
Ethics Committee, University of New South Wales, and followed the tenets of the Declaration of 13 
Helsinki.  14 
The nine Depression items from the Goldberg Anxiety and Depression (GAD) scale were 15 
used to screen for depressive symptoms. One point on this scale is given for every positive response 16 
and a score of 2 or greater indicates clinically significant symptomatology
14
. The GAD has excellent 17 
validity within an aged population
14, 15
 with a sensitivity of 86% and overall specificity of 91% in 18 
relation to diagnosed depression
14
. General health was assessed using the Medical Outcomes Study 19 
Short Form 36 (SF-36), The SF-36 represents multiple measures of physical and emotional health
16
. 20 
It comprises eight subscales: physical functioning, role-physical, role-emotional, bodily pain, general 21 
health, social functioning, mental health and vitality. It is scored on a range of 1 to 5 and transformed 22 
in accordance to the guidelines provided by Ware et al
16
 to a range of 0-100 where 0 correlates with 23 
worst possible score/function and 100 correlates with best possible score/function. The SF-36 has 24 
excellent validity (internal consistency α ~0.8)17. As a measure of comorbidity, the presence of each 25 
5 
medical condition was given 1 point from a list of nine system-related conditions (cardiovascular, 1 
respiratory, musculoskeletal, endocrine, urogenital, cancer, neurological, mental health, and eye 2 
diseases). Physical activity was measured using the Incidental and Planned Exercise Questionnaire 3 
(IPEQ) that was designed for use with older people
18
. IPEQ measures the number of self-reported 4 
hours of exercise including both planned and incidental activities and has good psychometric 5 
properties (test-retest reliability 0.77, and internal consistency 0.6)
18
. Total time spent is summed 6 
across all components and expressed as hours per week
18
. Assistance required for everyday tasks was 7 
assessed with questions relating to dependence on others (relatives, friends and community services) 8 
for basic tasks involved in daily living activities such as cooking, cleaning, and shopping. It was 9 
scored in a binary fashion with any assistance for any task being given a score of 1. 10 
Statistical analyses were performed using SPSS (Version 16.0). Several variables were 11 
transformed due to non-normal distributions based on a method suggested by Tabachnik and Fidell
 
12 
19
. A square root transformation was used for general health, physical functioning, mental health and 13 
IPAQ; a logmarithmic transformation was used for Role-physical, Role-emotional and social 14 
functioning subscales of the SF-36; FES-I; and an inverse transformation was used for the depression 15 
subscale of the GAD scale. Differences between people with AMD and controls were evaluated 16 
using independent t-tests. Associations among the quality of life measures were assessed with 17 
Pearson correlations, and a linear regression analysis was used to elucidate the impact of AMD 18 
(entered separately as the first block) and physical, health and lifestyle factors (entered together in 19 
the second block) on depressive symptoms, excluding all the subscales associated with psychological 20 
domains. Path analysis was performed using SPSS in conjunction with Analysis of Moment 21 
Structures (AMOS 18.0) Graphics. AMOS was used to examine whether the impact of AMD on 22 
depressive symptoms was direct or indirect over associated poor general health. Goodness-of-fit
20
 of 23 
the model was investigated by chi-square, Goodness-of-Fit Index (GFI) and Comparative Fit Index 24 
(CFI). Chi-square (χ2) is a statistical test of lack of fit resulting from over-identifying restrictions 25 
6 
placed on a model, and should not be significant. GFI should be high (>0.90) as it assesses the extent 1 
to which the model provides a better fit compared with no model at all [35]. CFI represents relative 2 
reduction in lack of fit as estimated by comparing the existing model with a null model that assumes 3 
latent variables in the model to be uncorrelated; high values (CFI>0.90) reflect a good model fit. 4 
Finally, standardized regression coefficients (rc), which are analogous to correlation coefficients, and 5 
explained variances were calculated. 6 
 7 
 8 
RESULTS 9 
 The mean ages of the AMD and control groups were comparable: 78.0 + 7.7 years and 78.1 + 10 
5.8 years respectively (t1,247=0.68, p=0.95). Both groups comprised similar proportions of men with 11 
53 (36.6%) in the AMD group and 30 (29.1%) in the controls (χ2= 1.49, df=1, p=0.22). Of a possible 12 
nine common medical conditions, the AMD group had a mean of 1.7 ± 1.0 and the control group 1.7 13 
± 0.9 (t1, 247=0.54, p=0.59). In the AMD group, 62 people (43.1%) lived alone compared with 54 14 
(52.4%) of the controls (χ2= 2.11, df=1, p=0.15) (Table 1). 15 
 Table 2 shows the GAD depressive symptoms, SF36 and IPEQ scale scores for the AMD and 16 
control groups. People with AMD performed significantly worse than the controls for the GAD 17 
depression scale and the SF-36 general health, physical functioning, social functioning and mental 18 
health subscales. For those with AMD, 63 (44.4 %) met the criteria for a clinically significant 19 
symptomatology compared with 18 (17.5%) of the controls (χ2= 19.5, df=1, p<0.001). Depressive 20 
symptoms were rare in the control population (3.3%) unless individuals had significant 21 
comorbidities. In the presence of a comorbidity score of >1, a control patient had a 30% chance of 22 
having depressive symptoms; a patient with AMD but no comorbidity, had a 36% chance of having 23 
depressive symptoms, and a patient with AMD and a comorbidity score >1 had a 62% chance of 24 
having depressive symptoms. The AMD group had higher physical activity levels but required more 25 
7 
assistance with activities of daily living. 56 (38.6%) of those with AMD required assistance with one 1 
or more activities of daily living compared with 5 (4.9%) of the controls (χ2= 37.0, df=1, p<0.001). 2 
 Table 3 shows the bivariate correlations among the depressive symptoms, physical activity 3 
and quality of life scales for the AMD group. Depressive symptoms were significantly associated 4 
with the mental health, physical functioning, social functioning, and vitality subscales of the SF-36. 5 
Linear regression analysis revealed that AMD could explain 7.2% of the variance in depressive 6 
symptoms when entered alone at an initial step. Three health and activity measures: poorer general 7 
health, higher levels of bodily pain, lower levels of social functioning and number of comorbidities, 8 
met the inclusion criteria at second step. Combined, these variables plus AMD explained 31% of the 9 
variance in AMD. The standardised beta weights were -0.27 for AMD, -0.17 for general health, -0.21 10 
for social functioning, -0.17 for bodily pain and 0.13 for comorbidity. The path analysis further 11 
examined the relationship between AMD and depressive symptoms (Figure 1). The results showed 12 
that 27% of the variance in the depressive symptoms was explained by the variables in this model, 13 
and that AMD led to depressive symptoms both directly and indirectly by reduced general health and 14 
social functioning. Goodness-of-fit indicators revealed that the model had a good fit (χ2(6)=22.45, 15 
p=0.001, GFI=0.97, CFI=0.93). 16 
 17 
 18 
DISCUSSION 19 
The current study confirms the high prevalence of depressive symptoms in older people with 20 
AMD, with nearly half of the AMD group having clinically significant depressive symptoms. Brody 21 
et al
8
, using previous studies of community samples, suggested that AMD was responsible for 22 
doubling the prevalence of depressive symptoms. Our study however indicates a much greater effect, 23 
where the presence of AMD may increase the risk of depressive symptoms in a person without 24 
comorbidity by 10 fold. 25 
8 
The study findings also indicate that people with AMD differ from their age-matched peers in 1 
measures of general health, physical and social functioning and requirements for assistance to 2 
undertake daily living activities - measures that are all associated with diminished quality of life
21
. It 3 
has been previously reported that people with AMD have a reduced quality of life as assessed with 4 
the SF-12
22
. The current study builds on this by more extensively assessing aspects of mood and 5 
quality of life. We found that people with AMD had significantly reduced physical and social 6 
functioning subscale scores even though they reported that their physical and emotional health did 7 
not interfere with their functioning (Role - Physical and Social). The AMD group also reported 8 
reduced mental health and general health scores even though there were no significant differences in 9 
reported comorbidities between the AMD and control groups. 10 
The linear regression analysis revealed that AMD was independently associated with 11 
depressive symptoms and that with the addition of three health and activity measures: poorer general 12 
health, higher levels of bodily pain, lower levels of social functioning and number of comorbidities, 13 
these measure could account for 31% of the variance in depressive symptoms. The path analysis 14 
provided a complementary analysis of “causal” pathways underlying depressive symptoms and 15 
showed that AMD led to depressive symptoms both directly and indirectly via reduced general health 16 
and social functioning.  17 
We acknowledge that the study has certain limitations. Firstly, data on the occurrence of 18 
recent major life events were not recorded. Therefore assumptions about the impact of this factor on 19 
depressive symptoms cannot be inferred from this study. Secondly, people with severe AMD were 20 
excluded, however we assume that people with more severe AMD would present with further 21 
reduced function and increased emotional distress. Thirdly, since all the patients were from semi-22 
urban and urban areas, the findings may not be generalizable to rural areas, where interactions 23 
between the level of social support and access to the health services may be different. Finally, we 24 
acknowledge that as we did not collect visual acuity data we are unable to determine whether AMD 25 
9 
directly causes depressive symptoms or causes depressive symptoms by reducing visual acuity. 1 
None-the-less we feel that the strong association found between AMD and depressive symptoms is 2 
clinically important and requires further research to elucidate underlying mechanisms and 3 
intervention possibilities.  4 
Consistent with previous studies
23-26
 our findings suggest that people with AMD have more 5 
depressive symptoms and a reduced quality of life. The current study adds to this work by 6 
delineating possible health and lifestyle mechanisms by which AMD may lead to these psychological 7 
and health conditions. Screening people with AMD with respect to depressive symptoms and their 8 
ability to perform everyday tasks, with subsequent referral for further evaluation and support 9 
services, could assist in maintaining the quality of life in this group 
27
.  10 
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Table 1: Demographics  of the study sample: AMD and control  2 
 AMD (n=145) 
Mean (SD) 
Controls (n=104) 
Mean (SD) 
Age 78.01 (7.73) 78.07 (5.8) 
Gender               Male 
                           Female 
53 
92 
31 
73 
Comorbidity 1.53 (1.21) 1.54 (1.07) 
Socioeconomic status 
Above average 
Below Average 
 
111* 
29* 
 
102* 
1* 
Living arrangements 
Alone 
With Spouse 
Spouse and children 
Children 
Relatives 
Other 
 
62 
54 
8 
13 
2 
5 
 
54 
31 
7 
5 
3 
3 
Chi-square test was performed for Gender, socioeconomic status and living arrangements and 3 
ANOVA was done for age difference between the two groups; *p<0.01, statistically significant.  4 
 5 
 6 
 7 
 8 
 9 
15 
Table 2: Depression, SF-36 and IPAQ scale scores: AMD and control comparisons 1 
Scale 
AMD (n=145) 
Mean (SD) 
Controls (n=104) 
Mean (SD)  
Depression 2.8 (2.1)* 1.7 (1.4) 
General health 59.42 (20.6) 63.42 (21.5) 
Physical functioning 52.27 (29.94)* 63.19 (24.42) 
Role- Physical 53.68 (40.82) 56.79 (40.32) 
Role – Emotional   71.27 (37.7) 74.66 (32.68) 
Vitality 52.84 (19.99) 55.27 (23.10) 
Bodily pain 60.76 (25.34) 62.37 (24.49) 
Mental health 73.87 (17.73)  79.80 (18.0) 
Social functioning 74.75 (25.66) 70.61 (21.72) 
IPAQ† 29.87 (13.19)* 22.23 (10.54) 
†Total hours of planned and incidental physical activity/week 2 
* p<0.01; ANOVA. 3 
4 
16 
Table 3: AMD Group: Pearson’s correlation co-efficients (R) for GAD depression, SF 36 and 1 
    IPAQ scales  2 
 3 
  
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
 
12 
 
13 
 
1 
 
0.20* 
 
0.28** 
 
-0.29** 
 
-0.21* 
 
-0.41** 
 
-0.25** 
 
-0.09 
 
-0.32 
 
-0.20 
 
0.41 
 
-0.35** 
 
-0.33** 
2 - 0.65** -0.53** -0.65** -0.27** -0.42** -0.19** -0.49** -0.32** 0.37** -0.35** 0.59** 
3 - - -0.53** -0.54** -0.43** -0.53** -0.29** -0.61** -0.33** 0.38** -0.38** -0.55** 
4 - - - 0.55** -0.38** 0.45** 0.18* 0.55** 0.31** -0.39** 0.48** -0.51** 
5 - - - -- 0.19* 0.35** 0.82 0.56** 0.24** -0.24** 0.31** 0.50** 
6 - - - - - 0.43** 0.35** 0.46** 0.35** -0.48** 0.41** 0.24** 
7 - - - - - - 0.25** 0.57** 0.44** -0.28** 0.41** 0.32** 
8 - - - - - - - 0.31** 0.22** -0.26** 0.18** 0.19** 
9 - - - - - - - - 0.42** -0.33** 0.47** 0.50** 
10 - - - - - - - - - -0.16* 0.38** 0.24** 
11 - - - - - - - - - - -0.25** -0.26** 
12 - - - - - - - - - - - 0.56** 
13 - - - - - - - - - - - - 
 4 
1 = ADLA: Assistance with Daily Living Activities; 2 = Anxiety; 3 = Depression; 4 = Social functioning; 5 = Mental health; 6 = 5 
Physical functioning; 7 = General health; 8 = IPAQ; 9 = Vitality; 10 = Body pain; 11 = MFES; 12 = Role – physical; 13 = Role – 6 
emotional 7 
* p<0.05, **p< 0.01 8 
9 
17 
Figure 1. Output of the path analysis. Values shown are standardized regression coefficients. 1 
Direct effects are provided next to each arrow and explained variances are provided in bold 2 
above each variable. 3 
Bodily pain
Comorbidities
AMD
General health
Social functioning
Depressive symptoms
0.14
-0.38
0.24
0.20
0.27
0.37
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0.10
0.44
-0.28
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-0.25
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